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a b s t r a c t
Eicosanoids, including cysteinylleukotrienes (cysLTs), are found in the central nervous system (CNS) of
individuals infected with HIV-1. Few studies have addressed the contribution of cysLTs in HIV-1-
associated CNS disorders. We demonstrate that conditioned medium from human astrocytes treated
with leukotriene C4 (LTC4) increases the transmigration of HIV-1-infected CD4þ T cells across an in vitro
blood–brain barrier (BBB) model using cultured brain endothelial cells. Additional studies indicate that
the higher cell migration is linked with secretion by astrocytes of CX3CL1/fractalkine, a chemokine that
has chemoattractant activity for CD4þ T cells. Moreover, we report that the enhanced cell migration
across BBB leads to a more important CD4þ T cell-mediated HIV-1 transfer toward macrophages.
Altogether data presented in the present study reveal the important role that LTC4, a metabolite
of arachidonic acid, may play in the HIV-1-induced neuroinvasion, neuropathogenesis and disease
progression.
& 2014 Elsevier Inc. All rights reserved.
Introduction
HIV-1 can invade the central nervous system (CNS) early during
the acute phase of the infection (Davis et al., 1992) via virus-
infected leukocytes (mostly monocytes and CD4þ T cells) and/or
circulating cell-free virions (Kolb et al., 1999; Wu et al., 2000).
Once in the CNS, the virus can productively infect several residing
cell types such as perivascular macrophages, microglial cells and to
some extent astrocytes (Anthony and Bell, 2008; Vincendeau et al.,
2010). Since the introduction of the highly active antiretroviral
therapy, the incidence of severe neurologic disorders such as HIV-
1-associated dementia has dropped drastically. However, patients
continue to show some CNS dysfunctions known as minor cogni-
tive motor disorder (Gonzalez-Scarano and Martin-Garcia, 2005).
More recently, a high prevalence of peripheral neuropathy has
been noted in HIV-1-infected individuals as well as a persistence
of neurological complications better known as HIV-1-associated
neurocognitive disorders (HAND) (Crossley and Brew, 2013). An
overall prevalence of HAND in patients with suppressed plasma
viraemia was found to reach 52% in the CHAPTER study (Cysique and
Brew, 2011). A strong correlation between HIV-1-associated neuro-
cognitive disorders and neuroinﬂammation in infected individuals
has been demonstrated (Adle-Biassette et al., 1999), possibly more so
than with the viral load found in the CNS (Gannon et al., 2011).
Elevated concentrations of bacterial lipopolysaccharide, cytokines,
viral proteins and eicosanoids present in the plasma of infected
individuals have been reported to increase the permeability of the
blood–brain barrier (BBB) (Strazza et al., 2011; Vincendeau et al.,
2010; Wang et al., 2008). Furthermore, in the context of HIV-1
encephalitis, a marked augmentation in matrix metalloproteinases
(MMPs) produced by astrocytes can be correlated with the disruption
of the BBB (Eugenin et al., 2006; Gramegna et al., 2011). Moreover,
certain chemokines produced in the CNS enhance neuroinﬂamma-
tion (such as IP-10, CCL2, MIP-1, CX3CL1 and IL-8) and may promote
HIV-1 neuroinvasion by attracting virus-infected leukocytes to this
immunologically privileged site (Becker, 2007; Clay et al., 2007;
Gesser et al., 1996; Kolb et al., 1999).
Leukotrienes (LTs) are potent proinﬂammatory lipid mediators
that display strong autocrine/paracrine activities and these are
produced by innate immune cells when challenged by a pathogenic
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agent. In stimulated cells, 5-lipoxygenase (5-LO) metabolizes arachi-
donic acid into either leukotriene B4 (LTB4) or cysteinylleukotrienes
(cysLTs) which include LTC4, LTD4 and LTE4. Once secreted, LTB4 can
engage BLT1 or BLT2 receptor, whereas cysLTs exert their effect on
receptors such as cysLT1, cysLT2 and GPR17 (Haeggstrom and Funk,
2011). Previous studies have reported that LTs along with their
cognate receptors are expressed in the brain, notably during HIV-1
infection (Basselin et al., 2011; Froldi et al., 1992; Matsuo et al., 1995).
Astrocytic endfeet are directly in contact with the BBB and
contribute in maintaining its integrity and homeostasis (Abbott
et al., 2010). Because astrocytes are the most abundant glial cells of
the brain and are known to release elevated levels of different
soluble factors including cysLTs, it is clear that these cells deserve
special attention based on the frequency of HIV-1-mediated
neurological complications. We thus assessed whether treatment
of astrocytes with LTC4 can result in production of soluble factors
that modulate transmigration of HIV-1-infected primary human
CD4þ T cells across a BBB model. We demonstrate here that
conditioned medium from LTC4-treated astrocytes enhances trans-
migration of HIV-1-infected CD4þ T cells via CX3CL1/fractalkine
production and promotes virus transfer to primary human macro-
phages.
Results
The cysLT 2 receptor is expressed on human astrocytes
We ﬁrst veriﬁed by ﬂow cytometry if human astrocytes express
LTB4 and/or cysLTs receptors. As illustrated in Fig. 1, both the
human astrocyticglioma U-87 MG cell line and primary normal
human astrocytes (NHA) express high levels of cysLT2. However,
no surface expression of the LTB4 receptor could be detected on
these cells (data not shown). Therefore, the following experiments
were carried out with LTC4 because it is considered as a potent
cysLT found in the CNS. The less active cysLT metabolite N-Acetyl-
LTE4 (N-Ac-LTE4), which is 100 times less potent than LTC4 as a
vasoconstricting agent (Foster et al., 1986), was used as a control in
our studies.
LTC4-treated astrocytes produce soluble factors that promote
transmigration of HIV-1-infected CD4þ T cells across BBB
endothelial cells
The protective immunosurveillance of the CNS is ensured
partly by CD4þ T cells. HIV-1 can take advantage of this inﬂux of
leukocytes to invade the CNS based on the idea that CD4þ T cells
act as a major cellular reservoir for this retrovirus. Therefore, we
set out to determine if soluble factors secreted by LTC4-treated
astrocytes could modulate the mechanism of HIV-1 trafﬁcking in
the CNS. This goal was reached by performing experiments with
the human cerebral microvascular endothelial cell line hCMEC/D3,
which closely mimics most of the key characteristics of the BBB
(Poller et al., 2008; Weksler et al., 2005). Permeability assays using
Blue Dextran showed that the barrier integrity of hCMEC/D3
monolayers grown on collagen-coated transwells (3 mm pore size)
was preserved for at least 48 h following conﬂuency (data not
shown). Next, we tested the effect of astrocyte-conditioned med-
ium on transmigration of primary human activated CD4þ T cells,
infected or not with HIV-1, across this BBB model. To this end,
astrocyte-conditioned medium was harvested from U-87 MG
astrocytic cells and NHA, which were either treated with LTC4,
N-Ac-LTE4, or left untreated. The astrocyte-conditioned medium
was placed in the lower chamber of the transwells. Finally, CD4þ
T cells infected or not with YU2, a brain-derived primary isolate of
HIV-1 that utilizes CCR5 as a co-receptor, were placed in the upper
chamber and transmigrated cells were quantiﬁed 24 h later.
Preliminary experiments utilizing supernatants from human astro-
cytes treated with increasing doses of LTC4 (i.e. 0.1, 1, 10 and
100 ng/ml) showed a statistically signiﬁcant induction of CD4þ
Fig. 1. Human astrocytes express the cysLT2 receptor. Human astrocytoma U-87 MG cells and NHA were incubated either with a rabbit anti-cysLT2 receptor antibody (black
line) or a rabbit isotype-matched irrelevant control antibody (gray line) followed by an anti-rabbit antibody conjugated with Alexa Fluors 488. The results shown are
representative of one out of a total of 4 independent experiments.
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T cell transmigration at 10 and 100 ng/ml, with a maximal effect at
the highest concentration used (data not shown). Therefore,
100 ng/ml of LTC4 was utilized for the following experiments. As
depicted in Fig. 2A, astrocyte-conditioned medium from LTC4-
treated U-87 MG cells induced a marked increase in transmigra-
tion of primary human CD4þ T cells compared to media. Cell
migration was not promoted when using astrocyte-conditioned
medium from U-87 MG cells either left untreated or exposed to
the less active analog N-Ac-LTE4. Interestingly, a comparable
enhancement in cell transmigration mediated by conditioned
medium from LTC4-treated U-87 MG cells was observed with both
uninfected (left panel) and HIV-1-infected CD4þ T cell cultures
(right panel). Initial transmigration studies revealed that condi-
tioned medium from LTC4-treated NHA was less powerful at
promoting migration of CD4þ T cells across hCMEC/D3 endothelial
cells (data not shown). Hence, CD4þ T cells were initially stained
with the Calcein AM ﬂuorescent dye prior to the transmigration
assay in order to more efﬁciently quantify the lower numbers of
transmigrated CD4þ T cells. In agreement with our observations
with U-87 MG cells, conditioned medium from LTC4-treated NHA
attracted more CD4þ T cells than conditioned medium from
untreated astrocytes (Fig. 2B). Again, treatment of astrocytes with
the less active analog N-Ac-LTE4 failed to induce any signiﬁcant
transmigration of CD4þ T cells across BBB endothelial cells. In all
these experiments, the β-chemokine RANTES was used as a
positive control while culture medium (i.e. DMEM supplemented
with 0.2% BSA) (called media) was used as a negative control for
transmigration assays. The use of RANTES in the current work is
Fig. 2. Conditioned medium from LTC4-treated astrocytes promotes transmigration of CD4þ T cells across a human BBB model system and enhances subsequent HIV-1
infection of macrophages. First, U-87 MG astrocytic glioma cells (A) and NHA (B) were either left untreated or treated for 24 h with LTC4, N-Ac-LTE4. Next, conditioned
medium from such untreated and treated astrocytes were placed under the lower chamber of transwells. In some samples, DMEM supplemented with 0.2% BSA (called
media/used as a negative controls) and RANTES (used as a positive control for CD4þ T-cell chemotaxis) were introduced directly into the lower chambers. Finally, primary
human activated CD4þ T cells either left uninfected or infected with HIV-1 (i.e. YU2) were placed in the upper chamber of transwells and allowed to migrate across a
monolayer of hCMEC/D3 human endothelial cells. In studies conducted with NHA (panel B), CD4þ T cells were initially stained with the Calcein AM ﬂuorescent dye prior to
their use. Transmigration of CD4þ T cells was estimated either by ﬂow cytometry (A) or ﬂuorometry (B). The means7standard deviations (SD) are calculated from
4 independent experiments with triplicate samples (Student t-test: n, po0.05; compared to untreated cells). (C) Primary human MDMs were cocultured for 24 h with HIV-1-
infected CD4þ T cells that had transmigrated in response to conditioned medium from U-87 MG cells either left untreated or treated with the listed stimuli. Virus production
was monitored 9 days following coculture of MDMs and transmigrated CD4þ T cells by quantifying the major viral core p24 protein, using an in-house ELISA assay. The
measured p24 contents for each condition were as follows: 4.072.8 ng/mL (untreated), 11.476.3 ng/mL (LTC4), 4.572.9 ng/mL (N-Ac-LTE4), and 5.372.1 ng/mL (RANTES).
To compensate for donor-to-donor infection variations, the results shown represent the means7SD calculated from 3 independent experiments and are expressed as fold
increase over media (A and B) or untreated cells (C) (Student t-test: npo0.05; compared to untreated cells).
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founded on the notion that activated CD4þ T cells are known to
express CCR5 on their membrane (Monteiro et al., 2011) and also that
this chemotactic agent is commonly used in cell transmigration assays
(Desmetz et al., 2006; Kawai et al., 1999). Importantly, attraction of
CD4þ T cells was not induced by media (DMEM/0.2% BSA) in which
LTC4 was added 24 h prior to the transmigration assay (data not
shown), thus demonstrating that the observed augmentation in cell
transmigration is not due to LTC4 by itself but is linked with one or
more soluble factor(s) secreted by LTC4-treated astrocytes.
Perivascular macrophages are the ﬁrst cells permissive to produc-
tive virus infection that circulating leukocytes infected with HIV-1 will
meet after crossing the BBB. Therefore, in order to monitor the
putative HIV-1 transfer from CD4þ T cells to macrophages, MDMs
were cocultured with HIV-1-infected CD4þ T cells that had transmi-
grated in response to astrocyte-conditioned medium. As shown in
Fig. 2C, MDMs produce more progeny virions when cocultured with
CD4þ T cells attracted by conditioned medium from LTC4-treated
astrocytes compared to CD4þ T cells that have transmigrated in
response to conditioned medium from untreated or N-Ac-LTE4-treated
astrocytes. We next veriﬁed if this higher HIV-1 transfer could be
explained by a modulatory effect exerted by the astrocyte-conditioned
medium from LTC4-treated cells on the virus infection levels of CD4þ
T cells. Although the astrocyte-conditioned medium did increase HIV-
1 infection in CD4þ T cells, possibly via some proinﬂammatory
cytokines, viral production levels were the same for target cells
exposed to conditioned medium from untreated, LTC4-, or N-Ac-
LTE4-treated U-87 MG astrocytic cells (data not shown). In parallel,
we also tested whether astrocyte-conditioned medium could mod-
ulate the infectious potential of YU2 virions through the use of TZM-bl,
an indicator cell line highly sensitive to HIV-1 infection. Our data did
not reveal any modulation of virus infectivity following exposure of
YU2 to conditioned medium from either untreated, LTC4- or N-Ac-
LTE4-treated U-87 MG cells (data not shown). Therefore, it can be
concluded that the enhanced virus production seen in MDMs results
from a physical contact with a higher number of HIV-1-infected CD4þ
T cells that have transmigrated across the BBB model system in
response to conditioned medium from LTC4-treated U-87 MG
astrocytic cells.
A recent work has monitored the HIV-1 infection rate of CD4þ
T cells from peripheral blood and it was estimated that 0.06% and
0.14% of circulating CD4þ T cells are infected with HIV-1 during
early and chronic infection, respectively (Josefsson et al., 2011).
Therefore, we next set out to determine whether cells productively
infected with HIV-1 and uninfected bystander cell populations (i.e.
Neighboring uninfected cells exposed to soluble factors released
by virus-infected cells) were attracted differently by conditioned
medium from LTC4-treated U-87 MG cells. To achieve this goal,
activated CD4þ T cells were ﬁrst infected with fully infectious
R5-tropic reporter viruses that encode for a cell surface molecule
called the murine heat-stable antigen (HSA/CD24) (used as a
reporter molecule). This unique tool permits to discriminate
between cells productively infected with HIV-1 (i.e. HSAþ) and
uninfected bystander cells (i.e. HSA) on the basis of HSA/CD24
surface expression. The mean percentage of activated CD4þ T cells
productively infected using this reporter virus was 5.3%, which is
in agreement with our previous observations (Imbeault et al.,
2009a, 2009b). The percentage of HIV-1-infected CD4þ T cells, as
monitored by HSA expression, was lower in the total cell popula-
tion attracted by conditioned medium from LTC4-stimulated
astrocytes (3.2%) than with conditioned medium from untreated
(4.9%) or N-Ac-LTE4-treated astrocytes (5.6%) (Fig. 3A). A dimin-
ished transmigration of CD4þ T cells productively infected with
HIV-1 was also seen when using RANTES (3.6%). However, even
though the percentage of HIV-1-infected CD4þ T cells is lower in
the transmigrated cell population in response to conditioned
medium from LTC4-treated astrocytes, the total number of virus-
infected CD4þ T cells (i.e. HSAþ) that have been attracted across
our BBB model is still higher when using such astrocyte-
conditioned medium (Fig. 3B).
LTC4 does not induce BBB disruption by increasing MMP-2 or MMP-9
production by astrocytes
It has been reported that astrocytes produce MMPs, which can
ultimately disrupt the BBB by degrading tight junction proteins
(Gramegna et al., 2011; Ivey et al., 2009). Of these, MMP-2 and
Fig. 3. Conditioned medium from LTC4-stimulated astrocytes drives transmigration of both uninfected bystander and HIV-1-infected CD4þ T cells. First, U-87 MG cells were
either left untreated or treated for 24 h with LTC4 or N-Ac-LTE4. Next, conditioned medium from untreated and treated astrocytes were placed under the lower chamber of
transwells. In some samples, RANTES was introduced directly into the lower chambers. Finally, primary human activated CD4þ T cells either left uninfected or infected with
fully competent reporter HIV-1 particles (i.e. NL4-3Bal-IRES-HSA) for 48 h were placed in the upper chamber of transwells and allowed to migrate across a monolayer of
hCMEC/D3 human endothelial cells. After 24 h, transmigrated cells were harvested and stained with the R-Phycoerythrin-conjugated anti-murine HSA/CD24 antibody. Cell
transmigration was assessed by ﬂow cytometry by quantifying the percentages of HIV-1-infected CD4þ T cells (i.e. HSAþ) (A) and total amounts of transmigrated CD4þ T
cells (i.e. uninfected and virus-infected) (B). Results shown represent the means7SD calculated from 4 independent experiments and are expressed as number of
transmigrated cells (Student t-test: npo0.05; compared to untreated cells).
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MMP-9, known to be produced by astrocytes, are often found in
the CNS of HIV-1-infected individuals and it was postulated that
they might play a key role in BBB disruption (Feng et al., 2011; Qiu
et al., 2011; Yang et al., 2007). We thus tested whether LTC4
treatment induces a deregulation of MMP-2 and MMP-9 secretion
by astrocytes. Zymography assays revealed that both U-87 MG
cells and NHA produce MMP-2 but not MMP-9 (Fig. 4A). None-
theless, LTC4 did not increase MMP-2 secretion by astrocytes nor
did it induce any MMP-9 production. In accordance with these
results, conditioned medium from LTC4-stimulated astrocytes
failed to signiﬁcantly increase the passage of a 70-kDa dextran-
conjugated ﬂuorescent dye through hCMEC/D3 monolayers
(Fig. 4B), suggesting a lack of effect on BBB integrity. To better
determine if the more robust transmigration of CD4þ T cells
induced by conditioned medium from LTC4-stimulated astrocytes
does not depend on the disruption of the in vitro BBB, chemotaxis
experiments were performed using collagen-coated transwells but
this time in absence of hCMEC/D3 cells. The results obtained from
the chemotaxis assays using such transwells showed a similar
effect of LTC4-treated astrocyte conditioned medium, although
with a much higher absolute number of transmigrated cells than
in the presence of a hCMEC/D3 monolayer (data not shown),
which suggest that BBB disruption does not play a signiﬁcant role
in the increased transmigration of CD4þ T cells induced by
conditioned medium from LTC4-treated astrocytes.
CX3CL1/fractalkine is involved in the LTC4-mediated increase in
transmigration of CD4þ T cells
We next set out to shed light on the LTC4-mediated soluble
factor(s) produced by human astrocytes that can drive transmi-
gration of CD4þ T cells across BBB endothelial cells. Since cysLTs
have been shown to induce IL-8 production in different cell types
(Rola-Pleszczynski and Stankova, 2007) and IL-8 acts as a potent T-
cell chemoattractant, we initially tested whether astrocytes could
secrete IL-8 upon treatment with LTC4. In our hands, LTC4 failed to
induce IL-8 secretion by astrocytes as opposed to TNFα and IFNγ
that were used as positive controls in this series of investigations
(data not shown). Thereafter, mRNA expression of several known
chemotactic molecules for CD4þ T cells (i.e. IP-10/CXCL10, MCP-1/
CCL2, MCP-2/CCL8, MCP-4/CCL13, MIP-1α/CCL3, MIP-3/CCL20, SLC/
CCL21, RANTES/CCL5, PARC/CCL18, TARC/CCL17 and fractalkine/
CX3CL1) was measured by quantitative real-time polymerase
chain reaction (qRT-PCR) in U-87 MG cells following LTC4 treat-
ment. Among these chemokines, only fractalkine/CX3CL1 showed
a signiﬁcant increase (4-fold) in mRNA expression in LTC4-treated
U-87 MG cells (Fig. 5A). To directly assess the implication of this
chemokine in the increased chemotactic potential of conditioned
medium from LTC4-treated astrocytes, we tested if a CX3CL1/
fractalkine blocking antibody could neutralize this phenomenon.
Data shown in Fig. 5B indicate that a CX3CL1/fractalkine blocking
antibody, but not an isotype-matched irrelevant control antibody,
reduces signiﬁcantly the increased transmigration of HIV-1-
infected CD4þ T cells in response to conditioned medium from
LTC4-treated U-87 MG cells (i.e. a reduction of 37.5715%). The
blocking antibody causes a comparable diminution when using
conditioned medium from TNFα- and IFNγ-treated U-87 MG cells,
which corroborates the importance of CX3CL1/fractalkine in the
increased transmigration of CD4þ T cells. To validate further the
role of CX3CL1/fractalkine in the more important cell migration
across the BBB experimental model system, we achieved gene
silencing using RNA interference (RNAi) technology. As depicted in
Fig. 6A, CX3CL1/fractalkine mRNA expression is efﬁciently attenu-
ated in U-87 MG cells following transfection of a pool of four
speciﬁc small interfering RNAs (siRNAs). Importantly, culture
medium from LTC4-treated astrocytes in which CX3CL1/fractalkine
mRNA expression has been reduced could no longer increase the
transmigration of HIV-1-infected CD4þ T cells across our BBB
model (Fig. 6B). Overall, these results indicate that the LTC4-
dependent secretion of CX3CL1/fractalkine by human astrocytes
is responsible for the enhanced transmigration of HIV-1-infected
CD4þ T cells through an in vitro model of BBB.
Discussion
It has been proposed that HIV-1 can invade the CNS via virus-
infected monocytes and CD4þ T cells that cross the BBB (Fischer-
Smith et al., 2001; Glass et al., 1995; Haas et al., 2000, 2003;
Harrington et al., 2005; Persidsky et al., 1999; Schnell et al., 2011;
Wang et al., 2008). Until now, most studies have focused on the
neuroinvasion of HIV-1 via monocytes. Nevertheless, the putative
mechanism(s) by which HIV-1-infected CD4þ T cells are attracted
in the CNS remains to be more fully elucidated. It has been shown
that the cysLT2 receptor is found in the CNS under pathological
conditions, often on astrocytes (Heise et al., 2000; Huang et al.,
Fig. 4. Conditioned medium from LTC4-treated astrocytes fails to induce disruption of the BBB: (A) U-87 MG astrocytic glioma cells and NHA were either left untreated or
treated for 24 h with LTC4 or N-Ac-LTE4. In some samples, cells were treated DMEM supplemented with 0.2% BSA (called media). Next, conditioned media from untreated and
treated astrocytes were subjected to an in situ zymography as described in “Materials and methods”. Results shown are representative of 3 independent experiments.
(B) Dextran-Rhodamine (12.5 mg) was placed over or below (100%) hCMEC/D3 monolayers grown on transwell inserts for 24 h before determining ﬂuorescence intensity
(540/625 nm) underneath transwells. Data shown represent the fold increase7SEM with respect to media calculated from 2 independent experiments.
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2008; Qi et al., 2011; Weksler et al., 2005; Zhao et al., 2011). In
corollary, our results indicate that the cysLT2 receptor is highly
expressed on human astrocytes (both a continuous cell line/U-87
MG and primary cells/NHA). As for cysLTs, they have been detected
in the cerebrospinal ﬂuid (CSF) of HIV-1-infected individuals
(Froldi et al., 1992, 1995; Genis et al., 1992), and they are also
present in infected brain tissues or virus-infected CNS cell types
(Basselin et al., 2011; Froldi et al., 1992, 1995; Genis et al., 1992;
Maccarrone et al., 2000).
We investigated whether treatment of human astrocytes by
cysLTs could mediate production of soluble factor(s) that can in
turn affect transmigration of HIV-1-infected CD4þ T cells across an
in vitro BBB model. Along with LTD4, LTC4 is known to be one of the
most potent cysLTs. Therefore, we used only LTC4 to stimulate
astrocytes since all cysLTs engage the same receptors. We report
here that conditioned medium from LTC4-treated astrocytes
induces a more potent transmigration of HIV-1-infected CD4þ
T cells across BBB endothelial cells than supernatants from
Fig. 5. Higher transmigration of HIV-1-infected CD4þ T cells in response to conditioned medium from LTC4-treated astrocytes relies on CX3CL1/fractalkine: (A) U-87 MG
cells were either left untreated or treated for 4 h with LTC4, N-Ac-LTE4, or a combination of TNFα and IFNγ before quantifying CX3CL1/fractalkine mRNA by qRT-PCR. Results
shown represent the fold increase7SD with respect to untreated cells calculated from 3 independent experiments. (B) U-87 MG cells were initially either left untreated or
treated for 24 h with LTC4, N-Ac-LTE4, or a combination of TNFα and IFNγ. Next, conditioned medium from untreated and treated astrocytes was incubated for 2 h at 37 1C
either with a neutralizing anti-CX3CL1/fractalkine antibody or an isotype-matched irrelevant antibody and next placed under the lower chamber of transwells. Finally,
primary human CD4þ T cells infected with HIV-1 (i.e. YU2) were placed in the upper chamber of transwells and allowed to migrate across a monolayer of hCMEC/D3 human
endothelial cells. The number or transmigrated cells was determined by ﬂow cytometry. The results shown represent the mean number of transmigrated cells7SD
calculated from 3 independent experiments with different PMBC donors and are expressed in folds over untreated cells (Student t-test: npo0.05; compared to untreated
cells).
Fig. 6. Silencing of CX3CL1/fractalkine in human astrocytes abrogates the LTC4-induced higher transmigration of HIV-1-infected CD4þ T cells: (A) U-87 MG cells were either
left untreated or transfected with CX3CL1/fractalkine-speciﬁc siRNAs (siCX3CL1) or a nontargeting control siRNA (siControl). Thereafter, CX3CL1/fractalkine mRNA levels in
transfected cells were quantiﬁed by qRT-PCR at 3 days following siRNA transfection. (B) Transfected cells were either left untreated or treated for 24 h with LTC4 or N-Ac-
LTE4. Next, conditioned media were then harvested and used in a transmigration assay with HIV-1-infected CD4þ T cells. Transmigrated cells were counted by ﬂow
cytometry. The results shown represent the mean number of transmigrated cells7SD calculated from 3 independent experiments with different PMBC donors and are
expressed in folds with respect to untreated cells (Student t-test: npo0.05: compared to untreated cells).
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untreated astrocytes. The LTC4-mediated enhancement in cell
transmigration was seen when using a ﬁnal concentration of
LTC4 (i.e. 100 ng/ml) that is somewhat higher than what is
measured in brains of HIV-1 transgenic rats or found in CSF
obtained from HIV-1-infected individuals (Basselin et al., 2011;
Froldi et al., 1992, 1995). However, it should be mentioned that the
microenvironment of astroglial cells in inﬂamed rodent brains
may not correlate with what is produced by astrocytes in humans
carrying HIV-1. Moreover, levels of LTs in CSF are probably an
underestimation of the amount produced in brain tissue. Indeed,
because LTs can be secreted locally by glial cells, concentrations
similar or higher to those used in our work are likely reached in
the microenvironment surrounding brain microglial cells based on
the notion that pg of LTs are measured per g of brain tissue.
In a search for the molecule(s) responsible for this increased
cell transmigration, we found that LTC4-treated human astrocytes
produce up to 4-fold more CX3CL1/fractalkine mRNA than
untreated astrocytes. The biological implication of this chemokine
in the enhanced transmigration of HIV-1-infected CD4þ T cells
was further conﬁrmed using a neutralizing antibody and siRNA-
based gene silencing. Additional experiments have been per-
formed with primary astrocytes (i.e. NHA) in an attempt to
validate conclusions made with the human astrocyticglioma cell
line U-87 MG. Unfortunately, we were unable to detect a statisti-
cally signiﬁcant difference in CX3CL1/fractalkine mRNA expression
(as assessed by qRT-PCR) between untreated and LTC4-treated
NHA (data not shown). This might be related to the previously
reported ﬁbroblast contamination seen in early passage cultures
prepared from dissociated CNS tissue (McCarthy et al., 1995).
Indeed, ﬁbroblast contamination is a widespread phenomenon
when culturing primary human cells since ﬁbroblasts display
faster generation times and can over populate more highly
differentiated cells in vitro (Pal and Grover, 1983). The possibility
that a ﬁbroblast contamination in NHA might act as a confounding
factor is fully supported by the demonstrated capacity of LTC4
to modulate some ﬁbroblast functions (Medina et al., 1994;
Phan et al., 1988), which in turn could affect the biology of
astrocytes. Moreover, it has been reported that ﬁbroblast cells
can express CX3CL1/fractalkine under different experimental con-
ditions (Husberg et al., 2008; Isozaki et al., 2011; Jones et al., 2013;
Ohta et al., 2010).
As reviewed previously, CX3CL1/fractalkine has been proposed
to play a pivotal role in spreading of HIV-1 infection in the
organism via virus-infected lymphocytes (Becker, 2007; Cotter
et al., 2002). Our data suggest that CX3CL1/fractalkine production
by astrocytes induced by the cysLTs LTC4 may also play an
important role in the HIV-1 neuroinvasion. Nevertheless, chemo-
taxis of CD4þ T cells is known to be induced by many other
chemokines, lipid mediators and interleukins. Additional studies
are needed to determine whether another yet-to-be deﬁned
soluble factor is produced by LTC4-treated astrocytes which may
also promote transmigration of HIV-1-infected CD4þ T cells across
BBB endothelial cells.
Since activated CD4þ T cells are known to be highly permissive
to HIV-1 infection, attraction of this cell population in the CNS by
LTC4-stimulated astrocytes may provide a renewed source of
target cells thus allowing a sustained viral replication in this body
compartment. We also provide evidence that the increased num-
bers of CD4þ T cells attracted across the BBB give rise to a more
potent infection in trans of macrophages, which constitute a stable
viral reservoir that facilitate spread of HIV-1. Therefore, it can be
speculated that stimulation of human astrocytes with cysLTs such
as LTC4 induces neuroinvasion and a sustained viral replication in
the CNS via a possible HIV-1 transfer to perivascular macrophages.
It is of interest to note that our data suggest also that
conditioned medium from LTC4-treated astrocytes attracts both
uninfected bystander cells and CD4þ T cells productively infected
with HIV-1 with a slightly higher efﬁciency for the former cell
population. It is possible that a fraction of HIV-1-infected CD4þ
T cells become less responsive to subsequent stimulation by the
chemotactic molecule CX3CL1/fractalkine, or yet again found to be
in an anergic state rendering them unable to efﬁciently transmi-
grate (Wherry, 2011). It has been reported previously that HIV-1
infection of leukocytes induces a better transmigration across the
BBB in response to the chemokine CCL2, due to an increased
expression of CCR2 (Eugenin et al., 2006). These data suggest that
such virus-infected cells do not lose their inherent ability to
transmigrate at least in response to CCL2. It is possible that HIV-
1-infected CD4þ T cells do not respond as well to CX3CL1/
fractalkine. The explanation for this discrepancy is currently
unknown but it should be stated that the experimental procedure
performed by Eugenin et al. (2006) does not permit to discrimi-
nate between migration of uninfected bystander cells versus HIV-
1-infected leukocytes. Nonetheless, ﬂow cytometric analyses of
the CX3CL1/fractalkine receptor CX3CR1 indicate that it is
expressed on CD4þ T cells that transmigrate in our assay. How-
ever, its surface expression level is comparable in transmigrated
HIV-1-infected CD4þ T cells upon exposure to culture medium
from human astrocytes either left untreated or treated with LTC4
or N-Ac-LTE4 (data not shown). It can be concluded that CX3CL1/
fractalkine does not seem to modulate its cell surface receptor
CX3CR1 level at least in transmigrating HIV-1-infected CD4þ
T cells.
Furthermore, we found that MMP-2 but not MMP-9 is pro-
duced by human astrocytes, and that LTC4 does not stimulate
secretion of MMP-2. In addition, LTC4 treatment does not induce
any alteration of the barrier integrity of hCMEC/D3 monolayer. The
neuroinvasion of HIV-1 via CD4þ T cells in response to condi-
tioned medium from LTC4-stimulated astrocytes is thus indepen-
dent of a BBB disruption caused by gelatin-binding MMPs. Several
studies have suggested that MMP activity is an important med-
iator involved in the BBB disruption seen in HIV-1-carrying
patients showing neurological disorders, and HIV-1 particles and
viral proteins (e.g. Tat and gp120) were shown to induce expres-
sion of MMP-2 and MMP-9 in astrocytes (Ivey et al., 2009;
Louboutin et al., 2010, 2011). We can thus propose a model for
HIV-1-related neuropathology in which physical damages to the
BBB are mostly caused by the virus itself, whereas cysLTs such as
LTC4 participate to the neuroinvasion process by inducing the
secretion of CX3CL1/fractalkine and other chemotactic molecules
by astrocytes.
Of course, further investigations will be needed to establish the
possible implications of the astrocyte secretome induced by LTC4
on a more physiological BBB model which would be also sheeted
by perivascular macrophages and pericytes. Indeed, infection of
astrocytes by HIV-1 was shown to compromise BBB integrity
through endothelial apoptosis, misguided astrocyte endfeet and
dysregulation of lipoxygenase/cyclooxygenase (Eugenin et al.,
2011). Analyzing the effect of LTC4 on the astrocyte–BBB relation-
ship in the context of HIV-1 infection would shed light on the
more precise mechanism(s) governing neuroinvasion and neuro-
pathology processes.
Conclusions
Our results underline the complex interplay between neuroin-
vasion and neuroinﬂammation in the context of HIV-1 infection.
The sustained prevalence of neurological complications that arise
in virus-infected individuals is intimately linked to the neuroin-
ﬂammation processes induced by HIV-1. Eicosanoids (such as
LTs and prostaglandins) – which are normally produced under
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pathological conditions – are known to negatively modulate HIV-1
infection in different cell types including some of which are found
in the CNS (Bertin et al., 2012). On the other hand, we show herein
that cysLTs, produced in the CNS of infected individuals, can
activate astrocytes and promote the neuroinvasion of HIV-1. In
vivo experiments with non-human primates should be considered
to better understand the overall contribution of LTs in the
neuropathogenesis of HIV-1 infection.
Materials and methods
Antibodies and reagents
LTC4 and its less active metabolite N-Acetyl-LTE4 were pur-
chased from Cayman Chemical (Ann Arbor, MI, USA). Surface
expression of LT receptors was determined by ﬂow cytometry
using either a rabbit anti-cysLT2 antibody (Cayman Chemical)
followed by a goat anti-rabbit antibody conjugated with Alexa
Fluors 488 (Molecular Probes, Burlington, Ont., Canada) or a
biotinylated anti-BLT1 antibody (Cayman Chemical) followed by
a streptavidin-R-phycoerythrin (BD Bioscience, Mississauga, Ont.,
Canada). Productive HIV-1 infection of primary human CD4þ
T cells with fully competent HSA-encoding reporter virus (see below
for more details) was assessed by ﬂow cytometry using the
R-phycoerythrin conjugated anti-HSA/CD24 antibody obtained
from BD Bioscience (Mississauga, Ont., Canada). The R-phycoerythrin
conjugated anti-CX3CR1 and its isotype-matched control antibody
were purchased from Biolegends (San Diego, CA, USA). The anti-
CX3CL1/fractalkine blocking antibody was purchased from R&D
Systems (Minneapolis, MN, USA). IL-8 was quantiﬁed using the BD
Biosciences Human IL-8 ELISA Set. High glucose DMEM and RPMI-
1640 media were purchased from Wisent Bioproducts (Montréal,
Que., Canada). Macrophage colony-stimulating factor (M-CSF) was
purchased from GenScript Corporation (Piscataway, NJ, USA).
Primers for PCR were purchased from Integrated DNA Technolo-
gies (San Diego, CA, USA). ThinCerts transwells (3.0 mm pore size)
were purchased from Greiner Bio-One (Frickenhausen, Baden-
Württemberg, Germany). Puriﬁed IFNγ and TNFα were obtained
from Biolegend (San Diego, CA, USA). Bovine serum albumin (BSA)
(20% sterile and ﬁltered solution) was purchased from Wisent
Bioproducts. All culture ﬂaks and plates were purchased from BD
Biosciences. Collagen and Blue Dextran (MW: 70 kDa) were
purchased from Sigma Aldrich (St. Louis, MO, USA). Calcein AM
was obtained from Invitrogen (Burlington, Ont., Canada), lithium
chloride (LiCl) was purchased from EMD chemicals (Gibbstown, NJ,
USA), whereas Dextran-Rhodamine ﬂuorescent dye (70 kDa) and
Lipofectamine™ RNAiMAX transfection reagent were purchased
from Life Technologies (Carlsbad, CA, USA).
Plasmids
pYU2 is a macrophage/CCR5-tropic HIV-1 molecular clone isolated
directly from human brain (obtained through the NIH AIDS Research
and Reference Reagent Program, Germantown, MD,USA) (Li et al.,
1991). The infectious molecular clone pNL4-3Bal-IRES-HSA was
recently described (Imbeault et al., 2009a). Brieﬂy, besides encoding
all HIV-1 proteins and producing R5 (Bal)-tropic virions, this NL4-3-
based vector additionally codes for the cell surface murine heat-stable
antigen (HSA)/CD24, enabling for efﬁcient early identiﬁcation of cells
productively infected with HIV-1.
Cell culture
The human glioblastoma-astrocytoma, epithelial-like cell line
U-87 MG was obtained from the American Type Culture Collection
(ATCC HTB-14, Manassas, VA, USA). NHA were purchased from
Lonza (Walkersville, MD, USA). In order to obtain astrocyte-
conditioned medium (additional details can be found in following
section entitled “Transmigration assay”), NHA were cultured in
astrocyte basal medium supplemented with astrocyte growth
medium (Lonza). Peripheral blood mononuclear cells (PBMCs)
from healthy donors were isolated by Ficoll-Hypaque gradient
(Wisent Inc., St-Bruno, QC, Canada). Next, PBMCs were plated at a
ﬁnal concentration of 1107 cells/ml in 75 cm2 ﬂasks (BD Bios-
ciences) for 2 h in order to separate by adherence monocytes from
the other non-adherent cells. After washing with endotoxin-free
phosphate-buffered saline (PBS) (Sigma-Aldrich), monocytes were
cultured in complete RPMI-1640 medium (that is RPMI-1640
supplemented with 5% heat-inactivated autologous serum,
100 U/ml penicillin G and 100 μg/ml streptomycin) in the presence
of M-CSF (10 ng/ml) for 6 days to obtain primary human
monocyte-derived macrophages (MDMs). Cells were then recov-
ered with a soft cell scraper and plated in 24-well plates at a ﬁnal
concentration of 1105 cells per well in RPMI-1640 medium
supplemented with 5% autologous serum. Non-adherent cells
obtained from the same donors were used to isolate CD4þ T cells
by a negative selection process using the EasySep CD4þ T cell
enrichment kit (Vancouver, BC, Canada). Cells were then activated
with the mitogenic agent PHA-L (1 mg/ml) for 3 days prior their
use and maintained in complete RPMI-1640 culture medium
supplemented with recombinant human IL-2 (30 U/ml) at a
density of 2106 cells/ml. Human embryonic kidney (HEK) 293T
(ATCC) and TZM-bl cells (NIH AIDS Research and Reference
Reagent Program) were cultured in complete Dulbecco's modiﬁed
Eagle's medium (DMEM), which was supplemented with 10%
heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin G
and 100 μg/ml streptomycin. The immortalized human cerebral
microvascular endothelial cell line hCMEC/D3, which has been
shown to constitutively express many endothelial and/or BBB
markers with the appropriate subcellular localization pattern,
was maintained in culture as described previously (Poller et al.,
2008; Weksler et al., 2005). The hCMEC/D3 cell line was a
generous gift from Dr. Couraud (Institut Cochin, France) under
the license from the Institut National de la Santé et de la
Recherche Médicale (INSERM, Paris, France).
Virus production
Viruses were produced by the calcium phosphate coprecipitation
method in 293T cells as described previously (Fortin et al., 1997). In
brief, 293T cells were transiently transfected with pYU2 and pNL4-
3Bal-IRES-HSA to produce fully infectious R5-tropic HIV-1 particles
and fully competent HSA-encoding reporter virions, respectively. Virus
preparations were normalized for virion content by using an in-house
enzymatic assay speciﬁc for the major viral p24 protein. In this test,
two distinct monoclonal anti-p24 antibodies (i.e. 183-H12-5C and 31-
90-25) are used in combination to quantify p24 levels (Bounou et al.,
2002). In addition, the infectivity of our virus stocks was assessed
using TZM-bl indicator cells. This cell line is a genetically modiﬁed
HeLa derived cell line expressing large amounts of cell surface CD4,
CCR5 and CXCR4 (Steckbeck et al., 2005). These cells carry separate
integrated copies of the luciferase and β-galactosidase genes under the
control of the HIV-1promoter and are highly susceptible to infection
with different variants (both R5- and X4-tropic). Virus preparations
that did not allow sufﬁcient reporter gene activity were discarded.
HIV-1 infection
PHA-stimulated primary human CD4þ T cells were inoculated
with a ﬁxed amount of YU2 virus (i.e. 10 ng of p24 per
1105 cells). Two days following HIV-1 infection, cells were
J. Bertin et al. / Virology 454-455 (2014) 128–138 135
thoroughly washed and resuspended in DMEM medium supple-
mented with 0.2% BSA for transmigrations assays. In some experi-
ments, virus-infected CD4þ T cells that had transmigrated across
our BBB model were thoroughly washed with HBSS 1X and then
cocultured with MDMs for 24 h. Thereafter, MDMs were thor-
oughly washed three times with HBSS 1X and incubated in
complete RPMI-1640 medium. No contaminated CD4þ T cells
could be observed by microscopy (data not shown). Cell-free
supernatants from MDMs were harvested 9 days post-infection
to quantify trans infection levels. Virus production was estimated
by measuring p24 levels in cell-free culture supernatants by ELISA.
Flow cytometry analysis
Before staining, cells were incubated for 15 min at 4 1C in PBS
containing 0.1% sodium azide, 10% heat-inactivated human ﬁbrin-
depleted plasma, 10% normal goat serum (Jackson ImmunoRe-
search Laboratories, West Grove, PA, USA) and 10% FBS to block
non-speciﬁc binding sites and washed once with PBS containing
0.1% sodium azide and supplemented with 5% FBS. To monitor cell
surface expression of LT receptors and CX3CR1, cells were incu-
bated with speciﬁc antibodies or with an appropriate isotype-
matched irrelevant control antibody (for non-speciﬁc staining) for
30 min at 4 1C. Cells were then washed with PBS supplemented
with 0.1% sodium azide and 5% FBS and ﬁxed in a 2% paraformal-
dehyde solution before analysis by ﬂow cytometry (Epics ELITE
ESP; Coulter Electronics).
Quantitative real-time polymerase chain reaction
For detection and quantiﬁcation of CX3CL1/fractalkine mRNA
(sense: GCAGCCTCACAGTCCTTACC; antisense: GTCTCTGCTCTGC-
CCATTTC), cells were either left untreated or treated for 4 h before
extracting total RNA which was puriﬁed utilizing the illustraRNAspin
RNA isolation kit (GE Healthcare life sciences, Piscataway, NJ, USA).
cDNAs were generated with the Moloney murine leukemia virus (M-
MLV) reverse transcriptase and random primers as indicated by the
manufacturer (Invitrogen). Ampliﬁcation of cDNA was achieved using
the SYBR Green PCR Master Mix (Life Technologies). To ensure
quantiﬁcation precision, all real-time PCR ampliﬁed samples were
normalized using the 18S housekeeping gene (sense: TAGAGGGA-
CAAGTGGCGTTC; antisense: CGCTGAGCCAGTCAGTGT). The cycling
conditions used for the Applied Biosystems 7500 sequence detection
system included a hot start (50 1C for 2 min and 95 1C for 10 min),
followed by 40 cycles of denaturation (95 1C for 15 s) and extension
(63 1C for 1 min) with end point acquisition.
Zymography assay
Gelatin zymography was performed as described previously with
slight modiﬁcations (Hu and Beeton, 2010). In brief, U-87 MG
astrocytic cells and NHA were cultured in 6 well plates (3.5105 cells
per well) for 24 h. Next, cells were either left untreated or treated with
LTC4 or N-Ac-LTE4 (100 ng/ml). Forty-eight hours post-stimulation,
culture medium for astrocytes (mock) or ﬁltered astrocyte-
conditioned medium was mixed with an equal volume of 2
zymography buffer (125 mM Tris hydrochloride [pH 6.8], 4% sodium
dodecyl sulfate (SDS), 20% glycerol and 0.25% bromophenol blue).
Then, samples were electrophoresed on a 10% (w/v) polyacrylamide
gel containing 0.1% (w/v) gelatin (MP Biomedicals, Solon, OH, USA).
After electrophoresis, the gel was washed for 30 min with 1
renaturating buffer (Novexs Zymogram from Invitrogen, Burlington,
Ont., Canada) followed by 30min incubation with 1 developing
buffer (Novexs Zymogram) with gentle shaking. After an overnight
incubation with a fresh solution of developing buffer at 37 1C,
gels were rinsed, stained for 1 h in Coomassie Brilliant Blue solution
(Bio-Rad laboratories, Mississauga, Ont., Canada), and then destained
in a 10% acetic acid and 30% methanol solution.
Transmigration assay
First, hCMEC/D3 cells were cultured in collagen-coated ThinCerts
transwells (12103 per transwell) for 7 days in complete EBM-2
culture medium in presence of 10 mM LiCl. To obtain astrocyte-
conditioned media, U-87 MG astrocytic cells or NHA were plated in
6 well plates (3.5105 per well) in DMEM medium supplemented
with 10% heat-inactivated FBS, 100 U/ml penicillin G and 100 μg/ml
streptomycin. One day after, cells were washed and stimulated with
LTC4 or N-Ac-LTE4 (100 ng/ml) in DMEM/0.2% BSA or left untreated for
24 h, before harvesting cell-free supernatants. PHA-activated primary
human CD4þ T cells either left uninfected or infected with HIV-1 were
resuspended in DMEM/0.2% BSA at a density of 20106 cells/ml. Next,
cells were overlayed on transwells (5105 per transwell). Alterna-
tively, CD4þ T cells were stained with the Calcein AM ﬂuorescent dye
(10 mM) for 30 min and then thoroughly washed before being
resuspended prior to transmigration. Thereafter, ﬁltered astrocyte-
conditioned medium (0.65 ml) was placed in the lower chamber. After
24 h, transmigrated CD4þ T cells were either counted by ﬂow
cytometry or quantiﬁed by ﬂuorometry at 460/520 nm (MLX micro-
titer luminometer, Dynex Technologies, Chantilly, VA, USA).
siRNA silencing of CX3CL1/fractalkine
U-87 MG were plated 24 h before transfection in 6 well plates
(3105 cells/well) in 2.5 ml of DMEM medium supplemented
with 10% heat-inactivated FBS without antibiotics. Cells were
transfected with 10 pmoles of CX3CL1/fractalkine-speciﬁc siRNA
(siGENOMESMARTpool, Thermoscientiﬁc Dharmacon) or nontar-
geting siRNA (AllStars Negative Control, Qiagen) using Lipofecta-
mine RNAiMAX as indicated by the manufacturer (Invitrogen).
Cells were washed at 24 h after transfection and cultured in fresh
media (DMEM/10% FBS without antibiotics). Forty-height hours
after transfection, astrocytes were either left untreated or stimu-
lated with 100 ng/ml of LTC4 or N-Ac-LTE4 for 24 h. Cells were then
lysed for CX3CL1/fractalkine mRNA quantiﬁcation and superna-
tants were utilized for transmigration experiments.
Statistical analysis
All experiments were repeated at least three times with different
donors for CD4þ T cells and MDMs, and each ﬁgure combines the
results obtained with all the different donors unless otherwise
speciﬁed. The statistical signiﬁcance of the difference between groups
was determined using the Student t-test. Calculations were made with
Prism version 3.03 (GraphPad Software Inc., La Jolla, CA, USA). The
P valueso0.05 were considered statistically signiﬁcant.
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